Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Sunday, December 14, 2014 10:18:47 AM
bullish
falling wedge breakout
$SGMO recent news/filings
## source: finance.yahoo.com
Fri, 12 Dec 2014 12:31:23 GMT ~ Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2%
read full: http://finance.yahoo.com/news/sangamo-biosciences-sgmo-jumps-stock-123123365.html
*********************************************************
Mon, 08 Dec 2014 12:35:16 GMT ~ Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
[at noodls] - December 8, 2014 Data Demonstrate Therapeutic Levels of Clotting Factor for Hemophilia in Non-Human Primates and In Vivo Protein Production of Lysosomal Storage Disease Enzymes RICHMOND, Calif., Dec. 8, ...
read full: http://www.noodls.com/view/33A671417680C5C572D3A7532CD47B589F985E81
*********************************************************
Mon, 08 Dec 2014 12:00:00 GMT ~ Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
[PR Newswire] - RICHMOND, Calif., Dec. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. "These data provide proof of concept for this broadly applicable genome editing strategy. We demonstrate that our process can be applied to multiple gene targets and is scalable to large animals supporting the potential application of the albumin gene as a safe harbor site for expression of therapeutic proteins," said Philip Gregory, D. Phil., Sangamo's senior vice president of research and chief scientific officer.
read full: http://finance.yahoo.com/news/sangamo-biosciences-presents-data-american-120000279.html
*********************************************************
Wed, 19 Nov 2014 13:12:21 GMT ~ Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
[at noodls] - RICHMOND, Calif., Nov. 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic® ...
read full: http://www.noodls.com/view/DD2E3FA030BA9F90ACB07ED56711CBCC7A2B10EC
*********************************************************
Wed, 19 Nov 2014 12:00:00 GMT ~ Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
[PR Newswire] - RICHMOND, Calif., Nov. 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic ...
read full: http://finance.yahoo.com/news/sangamo-biosciences-presents-study-society-120000792.html
*********************************************************
$SGMO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SGMO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SGMO/company-info
Ticker: $SGMO
OTC Market Place: Not Available
CIK code: 0001001233
Company name: Sangamo BioSciences, Inc.
Incorporated In: DE, USA
$SGMO share structure
## source: otcmarkets.com
Market Value: $1,130,717,674 a/o Dec 12, 2014
Shares Outstanding: 68,403,973 a/o Oct 22, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$SGMO extra dd links
Company name: Sangamo BioSciences, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SGMO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SGMO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SGMO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/news - http://finance.yahoo.com/q/h?s=SGMO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SGMO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SGMO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SGMO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sangamo+BioSciences%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sangamo+BioSciences%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sangamo+BioSciences%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SGMO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001001233&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SGMO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SGMO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SGMO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SGMO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SGMO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SGMO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SGMO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SGMO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SGMO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SGMO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SGMO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SGMO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SGMO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SGMO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SGMO
$SGMO DD Notes ~ http://www.ddnotesmaker.com/SGMO
Recent SGMO News
- Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) • Business Wire • 04/22/2024 08:35:00 PM
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering • Business Wire • 03/22/2024 12:05:00 PM
- Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/13/2024 12:05:00 PM
- Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs • Business Wire • 03/13/2024 12:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast • Business Wire • 03/12/2024 10:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:14:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:13:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:11:45 PM
- Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease • Business Wire • 02/12/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:35:43 PM
- Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile • Business Wire • 02/05/2024 11:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 04:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:42:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:42:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:41:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:40:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:39:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 12:55:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:20:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:19:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:19:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:18:40 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM